Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.
Mov Disord
; 33(4): 520-527, 2018 04.
Article
em En
| MEDLINE
| ID: mdl-29573469
ABSTRACT
Treatments to slow the progression of cognitive dysfunction to dementia and improve the quality of life of persons with Parkinson's disease (PD) are desperately needed. Because PD mild cognitive impairment is considered a transitional stage before dementia, it opens a window to timely intervention. This article critically reviews the strengths and challenges of pharmacologic and nonpharmacologic clinical therapeutic trials in PD mild cognitive impairment conducted during the past 5 years, including ongoing trials. Relatively few high-quality trials have been conducted, and some important factors in designing future clinical trials are discussed. © 2018 International Parkinson and Movement Disorder Society.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Ensaios Clínicos como Assunto
/
Disfunção Cognitiva
/
Testes Neuropsicológicos
Limite:
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article